NTLA Latest Headlines

Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws

at www.tipranks.com (Fri, 10-Apr 5:04 PM)

NTLA’s Lonvo-z Therapy Shows 96% Reduction in HAE Attacks: New Data Highlights Potential One-Time Treatment

Market Chameleon (Wed, 8-Apr 9:33 AM)

NTLA Awards 16,500 RSUs to New Employees Under Strategic Inducement Plan

Market Chameleon (Mon, 9-Mar 8:24 AM)

FDA Greenlights Intellia’s MAGNITUDE Phase 3 Trial: Nex-z Poised to Advance One-Time Gene Editing for ATTR-CM

Market Chameleon (Mon, 2-Mar 7:34 AM)

Intellia’s 2025 Results Highlight Durability of Gene Editing Programs and Solid Cash Outlook Through 2027

Market Chameleon (Thu, 26-Feb 8:10 AM)

NTLA Sets Date for 2025 Earnings Call—What Should Investors Watch Ahead of the Business Update?

Market Chameleon (Thu, 19-Feb 8:54 AM)

Intellia Grants 30,600 RSUs to New Hires—What the Latest Inducement Says About NTLA’s Growth Ambitions

Market Chameleon (Fri, 6-Feb 7:33 AM)

FDA Clears Path for Intellia’s MAGNITUDE-2 Trial—Enrollment Resumes for Promising One-Time Therapy

Market Chameleon (Tue, 27-Jan 8:21 AM)